Comparing the effectiveness of two medications for plaque psoriasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to compare the effectiveness of deucravacitinib and apremilast in adults diagnosed with plaque psoriasis. Participants will be newly initiating one of these medications and will be enrolled in the CorEvitas Psoriasis Registry, allowing for real-world data collection on treatment outcomes. The study will analyze patient-reported outcomes and clinical effectiveness over time, providing insights into which medication may offer better results for patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Have been diagnosed with plaque psoriasis by a dermatologist
* Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast)
* Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes

Exclusion Criteria:

* Participation (current or planned) in an interventional clinical trial (does not include observational registry or study)
* Restart of treatments with the study eligible therapies previously received at any time during the participants' treatment history

Where it's running

• Local Institution
  Waltham, Massachusetts, United States Recruiting

Study contacts

• Study coordinator: BMS Study Connect Contact Center www.BMSStudyConnect.com
• Email: Clinical.Trials@bms.com
• Phone: 855-907-3286

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating the effectiveness of deucravacitinib for plaque psoriasis in adults in France

  This study is testing how well deucravacitinib works for adults with moderate-to-severe plaque psoriasis in real life.

  Recruiting at 39 sites Bristol-Myers Squibb · Amiens and 47 other locations · NCT06701513

• HB0017 Injection safety and PK in low-weight adults at different injection sites

  This early-phase study tests a single subcutaneous HB0017 injection in healthy, low-weight adults and compares how the body processes the drug when injected at different sites.

  Recruiting Phase 1 Huabo Biopharm Co., Ltd. · Hangzhou, Zhejiang · NCT07920861

• MK-8644: first-in-human test in healthy people and people with psoriasis

  This early-phase study tests MK-8644 versus placebo in healthy volunteers and people with psoriasis to see if it is safe and tolerable.

  Recruiting Phase 1 Merck Sharp & Dohme LLC · Melbourne, Victoria · NCT07850310

• Is XJH05 Ointment Effective for Plaque Psoriasis?

  This study tests whether the XJH05 ointment can help people with plaque psoriasis compare to a calcipotriol ointment.

  Recruiting Xijing Hospital · Xi'an, Shaanxi · NCT07780929

• Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care

  This study looks at how well guselkumab works for people with moderate-to-severe psoriasis after switching from ustekinumab in everyday clinical practice.

  Recruiting Janssen-Cilag Kft. · Budapest · NCT07746583

• TQH3906 capsules vs warmer options in adults with moderate to severe plaque psoriasis

  This Phase 3 trial tests whether once-daily TQH3906 capsules can help adults with moderate to severe plaque psoriasis better than a placebo or the active drug deucravacitinib.

  Recruiting at 13 sites Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 44 other locations · NCT07724366

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.